First National Bank of Mount Dora Trust Investment Services Has $350,000 Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

First National Bank of Mount Dora Trust Investment Services decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 63.6% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 704 shares of the medical research company's stock after selling 1,229 shares during the period. First National Bank of Mount Dora Trust Investment Services' holdings in Thermo Fisher Scientific were worth $350,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in TMO. Cypress Advisory Group LLC acquired a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $253,000. Intact Investment Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 34.0% during the fourth quarter. Intact Investment Management Inc. now owns 2,600 shares of the medical research company's stock worth $1,353,000 after purchasing an additional 660 shares during the last quarter. Purkiss Capital Advisors LLC acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at $1,121,000. W.H. Cornerstone Investments Inc. lifted its position in Thermo Fisher Scientific by 25.1% during the fourth quarter. W.H. Cornerstone Investments Inc. now owns 2,870 shares of the medical research company's stock worth $1,493,000 after buying an additional 576 shares during the period. Finally, Van ECK Associates Corp lifted its holdings in shares of Thermo Fisher Scientific by 19.7% during the 4th quarter. Van ECK Associates Corp now owns 418,365 shares of the medical research company's stock worth $217,646,000 after acquiring an additional 68,927 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on TMO. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Citigroup cut their price objective on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Royal Bank of Canada reduced their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $605.30.

Thermo Fisher Scientific Price Performance

NYSE:TMO traded up $6.00 during trading hours on Tuesday, reaching $414.53. 2,573,612 shares of the company's stock were exchanged, compared to its average volume of 1,914,596. The company has a market capitalization of $156.48 billion, a P/E ratio of 25.08, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 12 month low of $390.50 and a 12 month high of $627.88. The business's 50-day simple moving average is $419.12 and its two-hundred day simple moving average is $494.94. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $5.11 earnings per share. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. Thermo Fisher Scientific's dividend payout ratio is 10.09%.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.